Arrowhead Research Corp., of Pasadena, Calif., said its next clinical candidate, ARC-AAT, an RNAi therapeutic designed to treat liver disease associated with alpha-1 antitrypsin (AAT) deficiency, greatly reduced both soluble and insoluble forms of inflammatory Z-AAT in the livers of PiZ mice after eight weeks of treatment in multidose studies.